Clinical Trial

Preclinical Assessment of an Engineered HMGB1 Protein as a Novel Companion Therapy for Muscular Dystrophies

Study acronym: HEAL-MD
Recruiting
View on ClinicalTrials.gov →
Summary
This is a monocentric, no-profit, retrospective and prospective observational cohort study conducted at IRCCS Ospedale San Raffaele. The study does not entail any additional procedures or interventions for participants. Biological samples (including blood/serum and muscle biopsies) are obtained for a previously approved study (LAMA2\_GUP24002) and collected under the existing BancaINSpe informed consent. For the present study, analyses will be performed on biospecimens already stored or that will be stored at BancaINSpe, using portions of material already collected for the LAMA2\_GUP24002 protocol.
Trial Details
NCT Number NCT07745218
Lead Sponsor IRCCS San Raffaele
Conditions LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)
Enrollment 25 participants
Start Date 2026-08-01
Primary Completion 2029-07 (estimated)
Study Completion 2029-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-04